Evidence map›Paper›PMID 28360208›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2017

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point

Steve Y Cho, Evan J Lipson, Hyung-Jun Im, Steven P Rowe, Esther Mena Gonzalez, Amanda Blackford, Alin Chirindel, Drew M Pardoll, Suzanne L Topalian, Richard L Wahl

Abstract readClinical Trial
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. The value ofEuropean journal of nuclear medicine and molecular imaging · 2021
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. The role of interimEuropean journal of nuclear medicine and molecular imaging · 2018
    Trial
  8. Absolute number of new lesions onEuropean journal of nuclear medicine and molecular imaging · 2018
    Trial
  9. [European journal of nuclear medicine and molecular imaging · 2026
    Review
  10. Article
  11. Compatibility of different PET/CT criteria in evaluating treatment response and survival in non-small cell lung cancer patients treated with immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  12. Review
  13. Article
  14. Imaging Immunotherapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  15. Article
  16. Approaches to Imaging Immune Activation Using PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Review
  17. Article
  18. Early-time-pointRadiology and oncology · 2025
    Article
  19. Review
  20. Review

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Steve Y ChoJohns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland scho@uwhealth.org.
Evan J LipsonJohns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Hyung-Jun ImUniversity of Wisconsin School of Medicine and Public Health and Carbone Comprehensive Cancer Center, Madison, Wisconsin.
Steven P RoweJohns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Esther Mena GonzalezJohns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Amanda BlackfordJohns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Alin ChirindelJohns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Drew M PardollJohns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Suzanne L TopalianJohns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Richard L WahlJohns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to evaluate

Indexed as

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyAdultAgedFemaleHumansMaleMelanomaMiddle AgedSignal TransductionTreatment OutcomeFluorodeoxyglucose F18FDGimmune checkpoint inhibitormelanomaPET/CTresponse assessment

Identifiers

PMID28360208
PMCPMC5577627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.